| Amy L Oxley, NP | |
|
500 Cherry St, Bluefield, WV 24701-3306 | |
| (304) 327-1656 | |
| (304) 325-1928 |
| Full Name | Amy L Oxley |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 500 Cherry St, Bluefield, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437551876 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | APRN74834-NP-C (West Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medexpress Urgent Care Inc West Virginia | 1254487101 | 115 |
News Archive
Researchers from the Higher School of Economics and the Turner Scientific and Research Institute for Children's Orthopedics have discovered that in children with arthrogryposis, the power of electrical activity in the brain cortex decreases, while its dynamics remains the same as in healthy children.
"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 5 days ago
| Entity Name | Greenbrier Emergency Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568401461 PECOS PAC ID: 2668377359 Enrollment ID: O20031205000043 |
News Archive
Researchers from the Higher School of Economics and the Turner Scientific and Research Institute for Children's Orthopedics have discovered that in children with arthrogryposis, the power of electrical activity in the brain cortex decreases, while its dynamics remains the same as in healthy children.
"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 5 days ago
| Entity Name | Wv Emergency Physician Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396979498 PECOS PAC ID: 6608929260 Enrollment ID: O20090729000327 |
News Archive
Researchers from the Higher School of Economics and the Turner Scientific and Research Institute for Children's Orthopedics have discovered that in children with arthrogryposis, the power of electrical activity in the brain cortex decreases, while its dynamics remains the same as in healthy children.
"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 5 days ago
| Entity Name | Medexpress Urgent Care Inc West Virginia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912133315 PECOS PAC ID: 1254487101 Enrollment ID: O20090918000219 |
News Archive
Researchers from the Higher School of Economics and the Turner Scientific and Research Institute for Children's Orthopedics have discovered that in children with arthrogryposis, the power of electrical activity in the brain cortex decreases, while its dynamics remains the same as in healthy children.
"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 5 days ago
| Entity Name | Island Medical Bluefield Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023561248 PECOS PAC ID: 3779871090 Enrollment ID: O20161019000815 |
News Archive
Researchers from the Higher School of Economics and the Turner Scientific and Research Institute for Children's Orthopedics have discovered that in children with arthrogryposis, the power of electrical activity in the brain cortex decreases, while its dynamics remains the same as in healthy children.
"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy L Oxley, NP 5665 New Northside Dr Ste 320, Atlanta, GA 30328-5834 Ph: (770) 874-6854 | Amy L Oxley, NP 500 Cherry St, Bluefield, WV 24701-3306 Ph: (304) 327-1656 |
News Archive
Researchers from the Higher School of Economics and the Turner Scientific and Research Institute for Children's Orthopedics have discovered that in children with arthrogryposis, the power of electrical activity in the brain cortex decreases, while its dynamics remains the same as in healthy children.
"Managing and Securing Mobile Healthcare Data and Devices," a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old.
Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.
› Verified 5 days ago
Wendy Kaye Lawless, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 701 Bland St, Bluefield, WV 24701 Phone: 304-800-5542 Fax: 304-325-5803 | |
Melissa D Lucado, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 701 Bland St, Bluefield, WV 24701 Phone: 304-800-5413 | |
Whitney Crook, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 Cherry St, Bluefield, WV 24701 Phone: 304-327-1500 | |
Kelli M Sarver, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: Rr 2 Box 378, Bluefield, WV 24701 Phone: 304-327-2410 Fax: 304-327-2410 | |
Bryan Bennett, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 Cherry St, Bluefield, WV 24701 Phone: 304-327-1656 | |
Ameneh Lambert, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 Cherry St, Bluefield, WV 24701 Phone: 304-327-1100 | |
Bobby G Gentry, APRN, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 512 Cherry St, Bldg. I, Bluefield, WV 24701 Phone: 304-324-2725 Fax: 304-324-2780 |